These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 22520134)

  • 41. Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants.
    Vesikari T; Prymula R; Schuster V; Tejedor JC; Cohen R; Bouckenooghe A; Damaso S; Han HH
    Pediatr Infect Dis J; 2012 May; 31(5):509-13. PubMed ID: 22228235
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix™) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007.
    Anh DD; Carlos CC; Thiem DV; Hutagalung Y; Gatchalian S; Bock HL; Smolenov I; Suryakiran PV; Han HH
    Vaccine; 2011 Mar; 29(11):2029-36. PubMed ID: 21256876
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa.
    Tapia MD; Armah G; Breiman RF; Dallas MJ; Lewis KD; Sow SO; Rivers SB; Levine MM; Laserson KF; Feikin DR; Victor JC; Ciarlet M; Neuzil KM; Steele AD
    Vaccine; 2012 Apr; 30 Suppl 1():A79-85. PubMed ID: 22520141
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Methodology and lessons-learned from the efficacy clinical trial of the pentavalent rotavirus vaccine in Bangladesh.
    Zaman K; Yunus M; El Arifeen S; Azim T; Faruque AS; Huq E; Hossain I; Luby SP; Victor JC; Dallas MJ; Lewis KD; Rivers SB; Steele AD; Neuzil KM; Ciarlet M; Sack DA
    Vaccine; 2012 Apr; 30 Suppl 1():A94-100. PubMed ID: 22520143
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rotavirus vaccines for the developing world.
    O'Ryan ML; Hermosilla G; Osorio G
    Curr Opin Infect Dis; 2009 Oct; 22(5):483-9. PubMed ID: 19623063
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A short report on highlights of world-wide development of RIX4414: a Latin American experience.
    Linhares AC; Ruiz-Palacios GM; Guerrero ML; Salinas B; Perez-Schael I; Clemens SA; Innis B; Yarzabal JP; Vespa G; Cervantes Y; Hardt K; De Vos B
    Vaccine; 2006 May; 24(18):3784-5. PubMed ID: 16098636
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Monovalent type 1 oral poliovirus vaccine in newborns.
    el-Sayed N; el-Gamal Y; Abbassy AA; Seoud I; Salama M; Kandeel A; Hossny E; Shawky A; Hussein HA; Pallansch MA; van der Avoort HG; Burton AH; Sreevatsava M; Malankar P; Wahdan MH; Sutter RW
    N Engl J Med; 2008 Oct; 359(16):1655-65. PubMed ID: 18923170
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transplacental rotavirus IgG interferes with immune response to live oral rotavirus vaccine ORV-116E in Indian infants.
    Appaiahgari MB; Glass R; Singh S; Taneja S; Rongsen-Chandola T; Bhandari N; Mishra S; Vrati S
    Vaccine; 2014 Feb; 32(6):651-6. PubMed ID: 24374502
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs.
    Patel MM; Parashar UD
    J Infect Dis; 2009 Nov; 200 Suppl 1():S291-9. PubMed ID: 19817612
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity of tetravalent rhesus rotavirus vaccine administered with buffer and oral polio vaccine.
    Ing DJ; Glass RI; Woods PA; Simonetti M; Pallansch MA; Wilcox WD; Davidson BL; Sievert AJ
    Am J Dis Child; 1991 Aug; 145(8):892-7. PubMed ID: 1650128
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The perspective of global eradication of poliomyelitis].
    Knolle H; Egli A; Candrian U
    Gesundheitswesen; 2004 Jan; 66(1):1-6. PubMed ID: 14767784
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq.
    Ciarlet M; Schödel F
    Vaccine; 2009 Dec; 27 Suppl 6():G72-81. PubMed ID: 20006144
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants.
    Vesikari T; Karvonen A; Bouckenooghe A; Suryakiran PV; Smolenov I; Han HH
    Vaccine; 2011 Mar; 29(11):2079-84. PubMed ID: 21238572
    [TBL] [Abstract][Full Text] [Related]  

  • 54. RotaTeq: Progress toward developing world access.
    Goveia MG; Nelson CB; Ciarlet M
    J Infect Dis; 2010 Sep; 202 Suppl():S87-92. PubMed ID: 20684723
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevention of rotavirus disease: guidelines for use of rotavirus vaccine.
    American Academy of Pediatrics Committee on Infectious Diseases
    Pediatrics; 2007 Jan; 119(1):171-82. PubMed ID: 17200286
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Update on Rotarix: an oral human rotavirus vaccine.
    O'Ryan M; Linhares AC
    Expert Rev Vaccines; 2009 Dec; 8(12):1627-41. PubMed ID: 19943758
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life.
    Block SL; Vesikari T; Goveia MG; Rivers SB; Adeyi BA; Dallas MJ; Bauder J; Boslego JW; Heaton PM;
    Pediatrics; 2007 Jan; 119(1):11-8. PubMed ID: 17200266
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oral iodine supplementation does not reduce neutralizing antibody responses to oral poliovirus vaccine.
    Taffs RE; Enterline JC; Rusmil K; Muhilal ; Suwardi SS; Rustama D; Djatnika ; Cobra C; Semba RD; Cohen N; Asher DM
    Bull World Health Organ; 1999; 77(6):484-91. PubMed ID: 10427933
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety of oral poliomyelitis vaccine: results of a WHO enquiry.
    Esteves K
    Bull World Health Organ; 1988; 66(6):739-46. PubMed ID: 3266113
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial.
    Madhi SA; Kirsten M; Louw C; Bos P; Aspinall S; Bouckenooghe A; Neuzil KM; Steele AD
    Vaccine; 2012 Apr; 30 Suppl 1():A44-51. PubMed ID: 22520136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.